Jul. 27, 1999 Sheet 10 Diarrhoea, particularly traveller's diarrhoea, can be caused by a change in the microorganisms of the gut.
Enterotoxigenic Escherichia coli (ETEC) infections are common and, as many holiday makers and busineSS travel lers can testify, can leave the Sufferer ambivalent about the Virtue of leaving his native country. E. coli is not the only aetiological agent: more Seriously, Vibrio cholerea, the caus ative agent of cholera, can cause diarrhoea as part of its Sometimes fatal mode of action.
Enterotoxigenic strains of E. coli (ETEC) are character ised by their ability to produce a heat-labile toxin (LT) and/or heat-stable toxin (ST). Some ETEC strains also produce pilus adhesins called colonisation factor antigens. These adhesins promote attachment of ETEC strains to the Small intestinal mucosa, thereby facilitating colonisation and delivery of enterotoxin. Diarrhoeal disease is ultimately dependent on production and efficient delivery of entero toxin.
The enterotoxins Stimulate Secretion by cells by activa tion of Signal pathways. Internal Signals within cells are carried by "Second messengers'. At least three signal path ways are known to be important for Secretion. One pathway employs the Second messenger cyclic adenosine monophoS phate (cyclic AMP). Another employs the Second messenger cyclic guanosine monophosphate (cyclic GMP). These two messengers are referred to as cyclic nucleotides. The third signal pathway (CA-dependent pathway) requires Ca" as the Second messenger.
The mode of action of LT is virtually identical to that of cholera toxin (CT), which has been well documented.
Briefly, the B protomer binds to a ganglioside receptor GM1
galactosyl-N-acetylgalactosaminyl-(N-acetyl-neuraminyl) galactosylglucosylceramide located on the brush border membrane. Recent studies have shown that LT also binds to a structurally related glycoprotein to which CT does not bind. Binding is followed by translocation of the A subunit through the membrane and release of the A1 fragment into the cytosol after proteolytic activation. Adenylate cyclase activity is stimulated following catalysing the NAD dependent cyclase complex. As a result, adenylate cyclase is locked into an active form through inhibition of an inherent feed-back regulatory mechanism which normally involves the hydrolysis of GTP to GDP and Pi. Inactivation of the regulatory Subunit leads to increased levels of the Second messenger, cyclic AMP. cAMP activates an enzyme called protein kinase A which, in turn, phosphorylateS proteins. The phosphorylation of proteins (that is, the addition of a phos phate group) results in the opening of chloride channels and therefore secretion. Increased levels of cAMP is also known to inhibit the absorption of NaCl.
The mode of action of ST is less well understood than that of LT STs produced by ETEC are a heterogeneous group of molecules having a molecular weight of from about 2000 to 5000 Da and which are non-antigenic in their native state. An example of a common ST is STI which can be either an 18 or a 19 amino acid peptide. In contrast to LT, which activates adenylate cyclase of intestinal cells, STI Stimulates only the particulate form of intestinal guanylate cyclase. The action of STI is almost instantaneous. The initial
Step in the biological action of ST is its interaction with membrane-bound guanylate cyclase in the cells, lead 2 ing to an increase in the intracellular concentration of cyclic GMP followed by activation of cyclic GMP-dependent protein kinase (protein kinase G). This culminates in the inhibition of Na' absorption and opening of chloride chan nels and, hence, Stimulation of Cl Secretion. ST-induced fluid secretion is relatively short-lived and is readily reversed, in contrast to the delayed but Sustained and irre versible effects of LT on adenylate cyclase and fluid secre tion. The intestinal ST I receptor has been shown to be a guanyl cyclase although other proteins or glycoproteins may also have a role.
Intestinal transcellular absorption and Secretion of elec trolytes is driven by the Na/K ATPase pump, located in the enterocyte basolateral membrane. Water flows passively with electrolytes in response to osmotic gradients, and Na and Clare the predominant ions involved in the absorption and Secretion of water. The absorptive and Secretory pro ceSSes in the Small intestine are separated. In general, electrolytes and water are Secreted from crypt enterocytes, and reabsorption takes place through Villus enterocytes. Normally, Secretion and absorption are balanced to prevent dehydration. The diarrhoeal response caused by LT and CT results from stimulation of a cAMP-mediated active secre tory mechanism (i.e. the cAMP pathway AS colonisation factors are is antigenically distinct, potential vaccines, must be multivalent. A prototype ETEC vaccine that contains known CFAS and outer membrane antigens associated with ETEC is being developed. To be completely effective, though, a vaccine would have to deal with all the adhesive factors synthesised by ETEC strains in the devel oping areas.
While the prospect of effective immunisation against diarrhoeal diseases of humans is appealing, effective vac cines are not expected to he available in the near future.
A further problem is that diarrhoea is not necessarily caused by microorganisms but may also be induced by other Secretagogues. Other Secretagogues include hormones, neurotransmitters, bile Salts, fatty acids and nutrients. Examples of diarrhoea include osmotically induced diar rhoea which is caused by lactose intolerance, malabsorption and diarrhoea caused by congential disorders. Of course, the antimicrobial drugs which are So often used in the treatment of infectious diarrhoea are completely ineffective in the treatment of non-infectious diarrhoea and the idea of immu nisation is also inapplicable. Alternative approaches to the treatment and prevention of ETEC and non-infectious diar rhoea are therefore being pursued.
The present invention relates to Such an alternative approach, and is based on the remarkable discovery that Such enzymes as lytic enzymes, especially proteolytic enzymes and mixtures of enzymes Such as bromelain and, in particular, Stem bromelain protease which is a component of bromelain can reduce toxin binding activity and can inhibit the secretory effect of toxins such as LT and CT and also toxins such as ST. This is in spite of the fact that, as discussed above, ST has a very different mode of action from LT and CT. As an added benefit, it appears that such enzymes can prevent attachment of enterotoxigenic bacteria to the human intestinal lining. Even more Surprisingly, Such enzymes also seem to inhibit Secretion induced by other Secretagogues and, thus, may also be effective in the treat ment of other, non-infectious, types of diarrhoea.
According to a first aspect of the present invention, there is provided the use of a lytic or other enzyme in the manufacture of a medicament for the prevention, manage ment or treatment of diarrhoea in humans.
WO-A-8801512 teaches that bromelain or other enzymes could be used in the treatment of Scour in piglets, but no disclosure was made either of the treatment of diarrhoea in humans or of the way in which the enzyme interferes with the diarrhoeal response to the toxin or other Secretagogue. In fact, Martindale (28th Edition, page 646) states that brome lain may actually cause diarrhoea in humans and So provides a powerful disincentive to investigating the use of bromelain or other proteolytic enzymes in the treatment of that condi tion.
Experiments which led to the making of this invention have shown, by the use of an ex vivo rabbit intestinal tissue model in USSing chambers, that bromelain and Similarly acting enzymes Significantly inhibited the Secretory effect of LT, CT and also ST; more specifically, bromelain and other proteases completely inhibited the net anion flux of Cl, and hence the Secretagogue effect of toxins Such as LT and CT and also ST and other Secretagogues unrelated to microor ganisms. The proposed mechanism of action of the enzymes is that they prevent attachment of toxin by modification of the toxin receptors located on the brush border membrane. It is also hypothesised that these enzymes have an additional mechanism for inhibiting fluid Secretion Since they appear to inhibit Secretion induced by prostaglandin E and by other There is now evidence that proteolytic enzymes Such as bromelain and stem bromelain protease, which is a compo nent of bromelain, have an effect on cyclic nucleotide pathways and this is explained more fully in the examples below. However, data indicate that the enzymes can also inhibit Secretion by factors which do not require cyclic nucleotides. For example, it seems possible that they may also inhibit Secretion by operating on the calcium dependent pathways. It is therefore possible that the enzymes may act, not on the different cyclic nucleotide pathways themselves but at the final step of the pathways which may be at the cell Surface. One theory which may explain the anti-Secretory activity of these enzymes is that, in fact, bromelain or, Specifically, the Stem bromelain protease component of bromelain may have some effect on the chloride or other channels either to prevent the channels from opening or to block them. Either of these actions would account for the anti-Secretory action of the enzymes but it should be stressed that the efficacy of enzymes Such as bromelain and Stem bromelain protease in the treatment of diarrhoea is not dependent on the accuracy of this proposal.
However, the Significant point about these observations is that enzymes Such as bromelain and Stem bromelain protease will inhibit Secretion caused by toxins and other Secretagogues which cause diarrhoea by different mecha nisms.
The enhancement of Sodium absorption by glucose did not appear to be Substantially affected by pre-treatment of tissue with bromelain in the same experimental model, this implies that protease does not result in extensive physiologi cal damage to the mucosa. Histopathological and electron microscopic examination of tissue revealed no morphologi cal abnormalities, thereby further confirming Safety of the treatment.
Furthermore, there is also Some evidence that proteolytic enzymes, particularly bromelain may also enhance absorp tion of Secreted fluid and nutrients as well as inhibiting Secretion. In another experimental model, the effect of bromelain treatment on other physiologically important receptors was tested. The influx of the amino acids, glutamic acid, lysine and leucine and of the dipeptide, glycine-phenylalanine was investigated.
Results from the influx studies revealed that there was no interference with glucose, amino acid and dipeptide influx, Supporting that bromelain has no adverse effect on receptors important for nutrient uptake. In fact, bromelain appeared to increase the absorption of these nutrients. This demonstrates that bromelain has an additional benefit other than just inhibiting Secretion and that is that bromelain will also increase absorption. This remarkable discovery indicates that bromelain would be effective in aiding recovery from diarrhoea by increasing fluid and nutrient absorption.
The A different experimental model, involving brush border vesicles, was used to investigate the use of protease in preventing attachment of colonisation factor antigen positive bacteria (CFA-positive bacteria) using enzyme immunoassay procedures.
Enzymes useful in the invention include lytic enzymes. Glycolytic enzymes Such as those with Sialidase, glycosidase, amylase and cellulase activity may be preferred, as may lipolytic enzymes. Proteolytic enzymes may be particularly useful in the invention. Although bro melain is the preferred proteolytic enzyme, others may be useful. Cysteine proteases form a Subclass of proteolytic enzymes which includes bromelain and papain. However, there is Some evidence that papain may be inhibited by cyStatins, whereas bromelain is not. Bromelain is therefore preferred. Other enzymes, Such as trypsin, may be useful.
Bromelain is the collective name for the proteolytic enzymes found in the tissues of the plant Bromeliaceae.
Bromelain is a mixture of various moieties derived from the Stem of the pineapple (Ananas COmosus). It contains at least two proteolytic enzymes but also non-proteolytic enzymes, including an acid phosphatase and a peroxidase; it may also contain amylase and cellulase activity. In addition, various other components are present, in particular, organically bound calcium. The known proteolytic enzymes of brome lain and papain share a high degree of amino acid Sequence homology around the active centre, and evidence Suggests that bromelain and papain use the same catalytic mecha nism. Bromelain differs from papain, however, in having a different specificity of cleavage. In addition, the known proteolytic enzymes of bromelain are glycoproteins, whereas papain is a simple protein. Bromelain is reviewed by Taussig and Batkin (J. Ethnopharmacol. 22 191-203 (1988) ).
AS early as the fifteenth century, bromelain has been used as a digestive aid, as a cleansing agent to improve the texture of skin, and to treat wounds to promote healing. Recently, a vast accumulation of knowledge on its pharmacological and biological effects have resulted in bromelain being available for clinical use in man. In particular, bromelain is used as an adjunct in the treatment of Soft tissue inflammation and oedema associated with trauma and Surgery. Bromelain is available in various countries under the trademarks ANAN ASE FORTE, ANANASE, EXTRANASE, PROTEOLIS, RESOLVIT, ROGORIN, BROMASE and TRAUMANASE.
In clinical use over a period of more than 30 years, there have been few reports of Significant undesirable effects.
In the past, bromelain has been used as the crude mixture of enzymes and other components without attempts being made to ascribe its activity to any particular component of the mixture. However, the present inventors have now found that one particular component known as Stem bromelain protease appears to be responsible for the anti-diarrhoea activity of bromelain.
Stem bromelain protease has been described by Ritonja et al (Febs Letters, 247, 419-424 (1989) ) and has the amino acid sequence set out below (SEQ ID NO 1): Therefore, in a further aspect of the invention there is provided the use of Stem bromelain protease having the amino acid sequence of SEQ ID NO 1 or a sequence Substantially homologous thereto in the preparation of an agent for the treatment or prophylaxis of diarrhoea in humans.
The term "substantially homologous' would be well understood by one skilled in the art who would easily be able to determine whether or not two Sequences were Substan tially homologous. However, in general, amino acid Sequences can be described as Substantially homologous when they have at least 40% homology although, for the purpose of the present invention, it is preferable for a sequence to have at least 50%, 60%, 70%,80%, 90% or 95% homology to the amino acid sequence of SEQ ID NO 1. In addition, the residues which are compared need not be in exactly the same positions in two Sequences which are Substantially homologous but rather, one of the Sequences may have various inserted or deleted amino acid residues or regions with respect to the Sequence with which it is compared.
The invention is particularly useful in the prophylaxis, management or treatment of enterotoxigenic E. coli infec tions. However, the invention may be equally effective in addressing diarrhoea caused by other toxins, for example the toxin of Vibrio cholerae. It may also be effective against any diarrhoea caused by organisms that elicit a Secretory process by opening of chloride channels or other channels. Moreover, bromelain would be expected to be effective 7 against any agent being infectious or non-infectious that mediates Secretion by activating Signal pathways, ie by either the cAMP, c0MP or calcium-dependent pathway. Examples of agents that cause disease by activating Signal pathways include the following organisms and their toxins: Bortadella pertuSSis, Salmonella Species, Campylobacter jejuni, Pseudomonas Species, Shingella Species, Yersinia enterOcolitica, Klebsiella pneumoniae, Clostridium dificile and enteropathogenic Escherichia coli.
To assist Survival of the proteolytic enzyme through the Stomach, it may be desirable to formulate the enzyme in an enteric-protected preparation. Enteric-coated tablets of bro melain are available (for example under the trademark ANANASE FORTE in the United Kingdom). Other orally administrable formulations include Syrups, elixirs, and hard and Soft gelatin capsules, which may also be enteric-coated.
Bromelain activity is stable over a wide pH range (pH 2-9). Therefore, it may not be necessary to enteric-protect (or enteric-coat) the bromelain or stem bromelain protease from the acid conditions in the Stomach. It may, however, be necessary to protect the enzyme from digestion by acid proteases in the gut. Bromelain or Stem bromelain protease may, therefore, be administered with a buffering agent, for example bicarbonate. Bromelain may be equally effective if administered alone in water or in a Solution containing nutrients to assist with absorption of fluid and nutrients. Examples of Suitable Solutions of nutrients are those rec commended by the World Health Organisation for Oral Rehydration Therapy.
The preferred delivery system would be controlled release of the enzyme, to ensure complete removal of receptor Sites along the intestine and/or exposure of all enterocytes to the protease. It would be desirable to have a combination of protection (to prevent digestion and absorption) and release all the way to the ileum.
Oral is preferred route of delivery. Dosage of bromelain is conventionally measured in Rorer units, FIPunits, BTU (bromelain tyrosine units), CDU (casein digestion units), GDU (gelatin digestion units) or MCU (milk clotting units). One Rorer unit of protease activity is defined as that amount of enzyme which hydroly ses a standardisation casein substrate at pH 7 and 25 C. So as to cause an increase in absorbence of 0.00001 per minute at 280 nm. One FIP unit of bromelain activity is contained in that amount of a Standard preparation, which hydrolyses a suitable preparation of casein (FIP controlled) under the Standard conditions at an initial rate Such that there is liberated per minute an amount of peptide, not precipitated by a Specified protein precipitation reagent, which gives the same absorbence as 1 umol of tyrosine at 275 nm. BTUs, CDUS, GDUs and MCUs are as defined in the literature, as follows: BTU One bromelain tyrosine unit is that amount of enzyme which will liberate one micromole of tyrosine per minute under the conditions of the assay (for example, after diges tion of an acid denatured haemoglobin Substrate at pH 5 and 30° C).
CDU
That amount of enzyme which will liberate one micro gram of tyrosine after one minute digestion at 37 C. from a standard casein substrate at pH 7.0.
GDU
The enzyme activity which liberates one milligram (10 g) of amino nitrogen from a standard gelatin Solution after 20 minutes digestion at 45 C. and at pH 4.5. 1100 BTU/g=750 CDU/mg=1200 GDU/g. Similar calculations can be carried out for pure Stem bromelain protease. While the precise dosage will be under the control of the physician or clinician, it may be found that daily dosages of from 50 to 4000 GDU/day is appropriate, for example from 100 to 1000 GDU/day. The daily dose may be given in one or more aliquots per day, for example twice, three times or four times a day.
The invention can be used in a method for the preparation, management or treatment of diarrhoea in humans, the method comprising administering to a Subject an effective amount of proteolytic enzyme.
The invention will now be described by the following examples. The examples refer to the accompanying drawings, in which: Because of the usefulness of the Ussing chamber model in monitoring toxin action, the effectiveness of many anti diarrhoeal drugs in reversing the Secretory action of toxins have been tested. This example relates to experiments designed to observe the use of protease in inhibiting LT toxin Secretory activity. Concurrently, the effect on the glucose Na" active co-transport function is monitored as an indicator of tissue viability.
Experiments Each surface of the tissue was continually bathed (10 ml per Surface) in freshly prepared Ringers buffer containing NaCl (53 mM), KCl (5 mM), NaSO (30.5 mM), mannitol (30.5 mM), NaHPO (1 69 mM), NaH2PO (0.3 mM), CaCl (1.25 mM), MgCl2 (1.1 mM) and NaHCO (25 mM). The bathing solution was maintained at 37 C. with water jacketed reservoirs connected to a constant-temperature cir culating pump and gassed with 95% O/5% CO.
The PD (the difference in voltage measured on the mucosal side versus the Serosal side of the tissue) and Is (the amount of current needed to nullify the PD) were then measured as previously described (Field et al., 1971 
loc cit).
A positive PD indicated that the serosal potential was higher than the luminal potential, that is the net flux from the mucosa (M) to Serosa (S) was positive. The tissue resistance (R) for each animal was also calculated from Ohm's Law where Is=PD/R, so that results between individual animals could be compared. Prior to mounting the tissue, the fluid resistance (R) was determined and incorporated into the calculations. Once the tissue was mounted and prior to experimentation, the Is, was determined at approximately 10 min. intervals until the tissue reached a steady State. Four Sections of tissue from the same animal were mounted Simultaneously and used for each experiment. To test for leakiness of the System owing to perforations of the ileal tissue, 200 ul of 0.5 mM solution of glucose and mannitol diluted in Ringers was added to the Serosal and mucosal Side respectively prior to experimentation.
Once the tissue reached equilibrium (time 0), the test material (0-100 ul) was added to the mucosal side. The same Volume of Sample was added to the Serosal Side to preserve osmotic balance. Variations in Is, PD and R were then recorded every 5-10 mins. At the end of every experiment, 200 ul of 0.5M glucose was added to the mucosal side of each chamber. Only those tissues that showed an increase in Is in response to glucose (indicating tissue viability) were included in the analysis. The increase in Is, upon glucose addition is due to enhancement of Na' absorption mediated by the electrogenic coupled transfer of Na" with glucose into the cell.
Pieces of rabbit ileum exposed to a range of concentra tions of bromelain (0-1000 tug/ml) for 30 min were exam ined by light microscopy and electron microScopy. Tissue exposed to PBS alone was used for comparison.
For light microscopy, tissue was fixed in neutral buffered formalin and Stained with haematoxylin/eosin and tissue gram Stain. Tissues for electron microscopy were fixed in 3% (v/v) glutaraldehyde/0.1M sodium cacodylate buffer (pH 7.4) and then stored at 4 C. until required.
1a Light MicroScopy
At examination of the tissues, particular attention was directed to morphological and Structural changes in both the intestinal villi and the brush border lining.
Tissue samples exposed to 1000 tug/ml of bromelain did not respond to glucose addition at the end of the treatment period, indicating that the tissue was no longer viable. Light 5,928,640 11 microscopic examination of these samples revealed pro nounced marked vacuolar degeneration. The Villus structure was absent and there was coagulation necrosis of individual epithelial cells lining the remnants of the Villus.
The ileal tissue that was treated with 50 tug/ml of brome lain was viable after glucose addition; however, the Is, response was not maximal, indicating Some necrosis of the tissue. Light microscopy confirmed this observation, whereby Samples exhibited Some coagulation necrosis of luminal epithelial cells and vacuolar degeneration, indicat ing dead or dying cells. The Villus architecture of these tissue preparations, however, remained intact.
Tissue treated with 10 ug/ml of bromelain had an intact mucosa with villi lined by tall columnar epithelium. In general the tissue appeared normal, yet occasional cells showed Some coagulation necrosis. There was a large response to glucose addition after 30 minutes of bromelain treatment, indicating healthy, viable tissue. The occasional cells that may have been affected by bromelain treatment, therefore did not appear to adversely affect the absorptive capacity of the tissue. 1b Electron Microscopy Examination of tissue treated with 10 ug/ml of bromelain by transmission electron microScopy revealed no morpho logical changes to the microVilli. The glycocalyx or mucus overlay was seen to be intact. where tissue was exposed to PBS only, there was a negli gible change in Is. Studies have shown that 40-60 min after CT addition there is a gradual progression to a maximal effect which occurred over the next few hours. Continuation of this effect occurred despite removal of all free toxin. Toxin that had been heat treated prior to exposure to the tissue had no effect. In addition, toxin exposed to the Serosal Side of the tissue had no effect on Is indicating that action only occurred after binding to receptors located on the brush border membrane.
Theophylline, a methylxanthine, was added to the Serosal Side of the tissue to observe the change in Is, due to cAMP. Theophylline inhibits cyclic nucleotide phosphodiesterases and thus elevates cAMP by inhibiting the conversion of AMP to 5'-AMP. The effects of theophylline, cAMP alone and Saturable amounts of CT on Na and Cl fluxes are the same. The effects of theophylline on flux, however, occur after only a few minutes.
Addition of theophylline (final concentration 5 mM) to the Serosal Side of the toxin-treated tissue resulted in a further increase in Is. The increase in Is due to theophyl line on PBS treated mucosa was equivalent to the final Is due to the combined toxin and theophylline treatment. This indicates that the change in Is, due to LT addition was due to the toxin action on cAMP and not by any other mecha nism. The same change in Is also showed that the amount of toxin and hence its activity used in this experiment was not maximal. That is, more toxin was required to occupy all receptors in order to exhibit maximal levels of cAMP and hence Isc.
At the completion of the experiment, glucose was added to the lumenal side of the chamber. This resulted in a further increase in Is, indicating that the tissue was viable. 12 Control chambers were included whereby bromelain (100 ug/10 ul) was first pre-incubated (30 min at 37° C) with an equal volume of an anti-bromelain antibody (IgG) (0.5 mg/ml) prior to addition to the chamber. Other chambers contained antibody or PBS alone. All chambers were then allowed to incubate for 30 minto enable Sufficient bromelain pre-treatment of the mucosal tissue. Prior to addition of toxin the chambers were completely emptied of Ringers (see above) and rinsed twice to ensure complete removal of antibody and bromelain. The chambers were then re-filled with fresh Ringers and the tissue allowed to stabilise. LT (2.5 Aug/ml) was then added to the mucosal side and the experi ment completed as described above.
FIG .2 shows the change in Is, produced by pre-treatment of tissue with bromelain or control Substance prior to addition of LT. In all control chambers, the Is, began to increase 40-50 min after addition of toxin as observed above. This result indicates that the anti-bromelain IgG and bromelain pre-incubated with antibody had no effect on the LT action. It also shows that changing the Ringers buffer had no effect on the tissue.
In chambers that were pre-treated with bromelain, there was no change in Is, after 60 min, indicating that the bromelain had completely inhibited the secretory effect of LT. Addition of theophylline to control chambers, showed a further increase in Is of 40% to 50%. In comparison, addition of theophylline to the bromelain treated chamber only showed a similar increase in Is. The final change in Is was therefore 40% to 50% less than that of the combined effect of LT and theophylline in control chambers. It is presumed that Some other mechanism of action of bromelain in inhibiting fluid Secretion may be present. Bromelain has been reported to inhibit the Synthesis of prostaglandins, which are known to inhibit cAMP production (Taussig and Batkin, 1988) . Other molecules that inhibit the synthesis of prostaglandins, including aspirin, indomethacin and ibuprofen, have also been shown to inhibit intestinal fluid secretion induced by bacterial toxins (Gots et al., 1974; Finch and Katz, 1972; Peterson et al., 1988) .
These data indicate that the bromelain had completely inhibited the net anion flux of Cl and hence Secretagogue effect of LT. The data also indicate that bromelain has an additional mechanism for inhibiting fluid Secretion, other than its ability to inhibit binding of toxin to intestinal receptors. The observation that total Is levels in bromelain treated tissue combined with prostaglandin (see Example 2b) or theophylline failed to reach the same levels as control tissues, Supports this hypothesis.
Addition of glucose at the end of the experiment showed a further increase in Is, therefore indicating that glucose Na" transport was unaffected. Because the enhancement of Na absorption did not appear to be substantially effected by pre-treatment of tissue with protease, the implication is that bromelain does not result in extensive physiological damage to the mucosa. This result is confirmed by the light microS copy study, referred to above and by influx studies described in Example 7b. Prefers to significance of differences (paired t-test) between bromelain-treated and control tissues when I and PD responses are maximal. PGE2, prostaglandin E: theo, theophylline; 8-Br-cGMP, 8-Bromo-CGMP.
Theophylline was added to the serosal side of the tissue when Is and PD values reached a plateau, indicating maximal effect of the toxin. Addition of theophylline at the end of the experiment showed similar increases in Is, and PD in both the bromelain-treated and PBS-treated tissue, as observed previously in LT experiments described in Example 1. This resulted in a final reduction in total Is and PD of 44% (combined effect of toxin and theophylline) in tissues treated with bromelain as compared to control tissues (Table 1 ). This observation Suggests that another mechanism for inhibiting fluid Secretion exists.
2b Effect of Prostaglandin E2 (PE2) on Is in bromelain treated tissue
To observe whether the reduction in total Is levels in bromelain treated tissue was because of reduced intracellular levels of cAMP as a result of reduced prostaglandin levels, exogenous prostaglandin was added to the Serosal side of the chamber when Is, and PD values had reached a plateau. PE2 (1x10M) was added instead of theophylline. The data presented in Table 1 of USSing chamber data, indicate that there is still a reduction of 48% and 64% respectively, in the total Is, and PD in bromelain and CT treated tissue, com pared with the combined effect of CT and PE2 in control (PBS treated) chambers.
These data Suggest the additional mechanism by which bromelain reduces fluid Secretion cannot be completely explained by its reported ability to inhibit the synthesis of prostaglandins. Significant reductions in total PD and Is values was observed as in earlier experiments when tissue was treated with bromelain prior to the addition of CT or LT. The final combined Is and PD values of control tissues treated with toxin followed by addition of theophylline or PE2, was Significantly higher than that of bromelain pre-treated tis SCS. It is hypothesised that bromelain has an additional mecha nism for inhibiting fluid secretion, other than inhibiting the ability of toxin to bind to intestinal receptors. If bromelain were to only prevent the attachment of toxin to the intestinal cells, all intracellular biochemical pathways would remain unaffected. The observation that total Is, and PD levels in bromelain-treated tissue fail to reach the same levels as PBS-treated tissue after addition of a second messenger (ie 8-Br-cGMP, PE2 or theophylline), implies that bromelain does affect an internal signals within cells. The ability of bromelain to reduce the total Is and PD changes induced by 8-Br-cGMP, implies an effect after cyclic nucleotide gen eration. Other molecules affect intracellular processes, for example chlorpromazine and indomethacin, however these molecules appear to be active only against Submaximal doses of toxin (ST). Furthermore, these molecules have been Experiments were conducted in a similar manner as for those described in Examples 1 to 3, with the exception that no bacterial toxins were used in these experiments. Brome lain or stem bromelain diluted in PBS (final concentration 15 ug/ml) were added to both sides of the ileal tissue. Control tissues were treated with PBS alone. Chambers were allowed to incubate for 30 minutes and rinsed as described The data presented demonstrate that bromelain and Stem bromelain are effective in inhibiting Secretion caused by increased intracellular levels of cyclic nucleotides. This finding Suggests that Stem bromelain protease is responsible for the anti-diarrhoea action of bromelain.
EXAMPLE 5
Effect of Bromelain on Secretion caused by theophylline and Prostaglandin E2 Experiments were conducted in a similar manner as for those described in Example 4. Bromelain diluted in PBS (final concentration 15 ug/ml) were added to both sides of the ileal tissue. Control tissues were treated with PBS alone. Chambers were allowed to incubate for 30 minutes and rinsed as described above. Theophylline (9 mg) or prostag landin E2 (1x10M) enhance absorption is also a remarkable discovery in that it demonstrates that bromelain will be effective in both treating and preventing diarrhoea. 7b Increase in absorption of nutrients These experiments were conducted to demonstrate the effect of bromelain on other physiologically important receptorS required for nutrient uptake. These Studies lead to the discovery that bromelain could also enhance the absorp tion of nutrients.
Influx Experiments. We tested glucose influx (initial rate & Rubino, A. (1988) Gut, 29, 366-371) . Influx of the amino acids, glutamic acid, lysine, leucine and the di-peptide, glycine-phenylalanine, was also studied.
New Zealand White rabbits were killed by chloroform inhalation. A 25 cm Segment of ileum, was excised, opened along the mesenteric border and rinsed free of intestinal contents with cold Ringer's Solution. Two 10 cm Segments of intestine were rapidly mounted in lucite influx chambers, where four adjacent portions of the mucosal side (Surface area of 0.28 cm ) were exposed to the preincubation solution for 30 minutes at 37° C. and gassed with 95% of O/5% of CO. The pre-incubation Solutions contained bromelain at 1 mg/ml for Studies observing glucose influx, and 15 lug/ml for amino acid and dipeptide influx. Control tissues were incu bated with Ringer's alone. Studies commenced when the preincubation Solution was replaced with Solutions of Same composition, but with the presence of C-labelled nutrient and H-Inulin as a marker of extracellular space. Incubation 5,928,640 17 18 in this solution was for 45-50 seconds and was stopped by cellular material was suspended in 2 ml cold Tris-HCl (pH quickly removing the Solutions containing label and adding 7.4) and filtered through a 1 mm Buchner funnel to remove cold 0.3M mannitol. Each piece of exposed tissue was then connective tissue and muscle fibres. The mucosal cell Sus punched out, gently blotted on filter paper, homogenised in pension was hypotonically disrupted by dilution (1:6) with 10% trichloroacetic acid and centrifuged to sediment par-5 cold distilled water and then homogenised in a SORVALL ticulate matter. Aliquots of the Supernatants were assayed for blender at full speed for 2 min. (The word SORVALL is a radioactivity with Hpb Beckman Scintillation fluid, in a trade mark.) The microSomal fraction was then precipitated
Beckman LS 7500 Beta-counter. Calculations were conwith concentrated MgCl2 or Solid CaCl2 (final concentration ducted as previously described (Rubino, A. Field, M. & 10 mM) and centrifuged at 2,900xg for 20 min. The pellet Schwachmann, H. (1971), J. Biol. Chem, 246,3542-3548) . 10 obtained was discarded and the Supernatant fluid filtered Table 2 shows the effect of bromelain on nutrient influx. through cheese cloth and re-centrifuged at 27,000xg for 30
The data show that there is no interference with glucose and min to pellet the crude brush border material. The Superna amino acid influx, indicating no adverse effects on other tant fluid (S1) was retained and stored at -20° C. until receptors important for nutrient uptake. The data also reveal required. The crude brush border material was Suspended in that treatment of intestinal tissue increases the absorption of 15 10 ml distilled water, to which 10 ml Tris-HCl (1.4M, pH nutrients. 7.4) and NaCl (0.15M) were then added. The suspension (n = 6) (n = 6) (n = 6) (n = 6) (n = 3) (n = 4) (n = 4) (n = 2) (n = 6) (n = 6) (n = 6) (n = 6) (n = 2) (n = 4) (n = 4) (n = 4) * Data are means + SE for n animals. Difference between means is not statistically significant. **Concentration of bromelain used to treat cells for amino acid influx and glucose influx experiments was 10 ug/ml and 1 mg/ml, respectively. Gly-Phe, glycine-phenylalanine: Glut. Ac., glutamic acid.
EXAMPLE 8 was homogenised with 5 Strokes in a P/E homogeniser at 1,000 rpm and centrifuged at 27,000xg for 30 min. The pellet containing brush border vesicles (BBV) was sus pended in PBS for testing by EIA and for antiserum (anti Similar procedures to that described by Laux et al BBV IgG production. were used. (These authors immobilised intestinal mucous sodium bicarbonate buffer (NaHCO/Na2CO, 0.1M, pH preparations on Wells and Subsequently treated coated wells 9.6) and adsorbed to wells by incubation overnight at 4 C. with enzyme; this was used to determine the effects of The effect of enzyme on LT-binding was then determined enzyme treatments on calf and mouse mucosal preparations by inoculating BBV coated wells with papain diluted 0.1% in attempts to elucidate the nature of K99 and K88 as to 0.00625% (w/v) in PBS. The plates were incubated for receptors.) 30 min at 37 C. and then washed and blocked and the assay In the current study, brush border vesicles (BBV) were completed in the usual manner. Pure LT (1 lug/ml) was used used as the test material. BBV were first prepared and then as the toxin preparation in the binding assay. Control experi immobilised on the Solid phase as follows:
ments were conducted where BBV were incubated with Briefly, crude mucus was obtained from human small 50 enzyme plus inhibitor, or Working dilution buffer (WDB)
intestine by means of a method derived from that of Laux et only (FIG. 15) . WDB contains phosphate buffered saline al, loc. cit. Brush border vesicles were Subsequently pre-(0.1M, pH 7.4, PBS) to which bovine serum albumin O.25% pared by the method of Chandler "Inherited Resistance to (w/v), BSA, ethylenediamine tetra-acetic acid, disodium K88" Escherichia coli in Pigs", PhD Thesis, La Trobe salt (1 mM, EDTA), polyoxyethylenesorbitan monolaurate University, Bundoora, Victoria, Australia (1986) ). This pro-55 0.05% (v/v), Sigma, Tween 20 and NaNs 0.1% (W/v) had cedure was derived from the methods of Christiansen and been added. Carlsen (Biochim. Biophys. Acta. 647 188-195 (1981) ), The enzyme immunoassay used is illustrated in FIG. 11 ; Carlsen et al, Biochim. Biophys. Acta. 689 12-20 (1982) ) details of it are as follows:
and Schmitz et al., (Biochim. Biophys. Acta. 323 98-112 Routine assays consisted of BBV immobilised to the (1978) ). The details are set out in the following paragraph. 60 wells of microtitre plates. The immobilised BBV were used
Human intestinal jejunal material was thawed in cold to bind E. coli LT toxin. The presence of bound toxin was Tris-HCl (12 mM, pH 7.4), the villous surface gently then detected by adding in turn, rabbit anti-LT IgG, urease Scraped with a microScope slide and Scrapings Suspended in conjugated Sheep anti-rabbit IgG, and enzyme Substrate WDB. The suspension was then centrifuged at 27,000xg for Solution. 15 min to remove particulate and cellular matter. Superna-65 Immobilisation of BBV on Solid Phase tant material, hereafter called crude mucus (CM), was Disposable polystyrene microtitre plates (Nunc retained and stored at -20° C. until required. The pelleted Laboratories, Roskilde, Denmark) were used for all assays. BBV 1:50 (v/v) were diluted in sodium bicarbonate buffer (NaHCO/Na2CO; 0.1M, pH 9.6) and adsorbed to wells by incubation overnight at 4 C. Typically, 100 ul was added to each well. Alternatively, plates could be coated by incuba tion for 2 h at 37 C. Coated plates could be stored at 4 C. for 1-2 weeks until required.
Active binding sites remaining on Wells after coating were routinely blocked by incubation (30 min at 37 C.) with bovine serum albumin1% (w/v), Sigma, BSA dissolved in PBS.
Diluents and Washing Procedures
The buffers used in all EIA assays performed in microtitre plates were based on PBS (0.1M, pH 7.2). WDB was generally used as the diluent for Suspending Samples and reagents. WDB containing ovalbumin (from chicken egg) 1% (w/v), grade II, Sigma was used as the diluent for enzyme conjugates. Optimum dilutions (for specific activity and economy) of coating agents, antigens, detection anti bodies and conjugates were estimated by crossed (checkerboard) titrations.
All incubation Steps, excluding the coating procedures, were performed at 37 C. for 30 min. Between each of the Steps, Supernatant liquid was removed from the Wells which were then washed three times with washing buffer consisting of PBS to which Tween 200.05% (v/v) had been added.
Prior to the incubation with Substrate, wells were washed with distilled water to remove any effect of residual buffer on Substrate (pH sensitive) Solutions.
Use of Urease Conjugates and Substrate
Urease-conjugated Sheep-anti-rabbit IgG (whole molecule) was purchased from Allelix and Sigma.
Urea substrate 0.008% (w/v) bromocresol purple pH indicator, 0.1% (w/v) urea; 0.00074% (w/v) disodium salt EDTA in dHO; pH 4.8 was used to detect the presence of bound conjugated (urease) enzyme, where a positive reac tion was evident from a distinct colour change from yellow to purple (Chandler et al., 1982) . This colour change is attributed to the action of urease enzyme on urea, resulting in production of ammonia and a consequent rise in pH. Colour development in Wells was measured by means of a TITERTEK MULTISKANTC plate reader (Eflab), as absor bance at 540 nm (Aso). (The expression TITERTEK MUL TISKAN TC is a trade mark.)
The action of bound urease (and hence specific colour development) could be stopped by addition of aqueous of thiomersal 0.025% (w/v) to test wells (10 ul/well).
Treatment of BBV with papain resulted in complete reduction of LT-binding activity. The effects of lower con centrations of enzyme and an endpoint of enzyme activity, however, were not determined. Incubation with enzyme and inhibitor or WDB only had negligible effect on EIA activity. It is possible that the disruptive effect of LT-attachment was not due to modification of BBV receptors, but due to effects of protease on the Solid phase coating. In order to investigate this possibility, anti-BBV IgG was used to detect the pres ence of BBV after protease treatment (FIG. 13) . Papain treatment of the BBV-coated solid phase resulted in a slight reduction in EIA activity. This was taken as an indication that the BBV Solid phase was largely unaffected by protease treatment. The reduction in EIA activity observed after protease treatment of BBV was therefore largely due to the effect on LT receptors located on the BBV.
EXAMPLE 9
The Influence of Protease on Attachment of Intestinal Brush Border Vesicles (BBV) to Colonisation Factor Antigens (CFA) in the EIA
